ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · Real-Time Price · USD
21.58
-0.22 (-1.01%)
Oct 6, 2025, 2:56 PM EDT - Market open
-1.01%
Market Cap3.64B
Revenue (ttm)1.02B
Net Income (ttm)222.16M
Shares Out 168.71M
EPS (ttm)1.33
PE Ratio16.28
Forward PE34.06
Dividendn/a
Ex-Dividend Daten/a
Volume998,377
Open21.80
Previous Close21.80
Day's Range21.32 - 21.94
52-Week Range13.40 - 26.65
Beta0.75
AnalystsBuy
Price Target29.25 (+35.54%)
Earnings DateNov 5, 2025

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2004
Employees 654
Stock Exchange NASDAQ
Ticker Symbol ACAD
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 21 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $29.25, which is an increase of 35.54% from the latest price.

Price Target
$29.25
(35.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

ACAD's thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD's Q2 2025 revenues remain solid with Nuplazid and Daybu...

7 hours ago - Seeking Alpha

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Con...

4 days ago - Business Wire

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperph...

12 days ago - Benzinga

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Acadia Pharmaceuticals said on Wednesday that its experimental therapy to treat a rare metabolic condition failed to meet the main goal in a late-stage study.

12 days ago - Reuters

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (...

12 days ago - Business Wire

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported...

23 days ago - Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in...

27 days ago - Business Wire

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Catherine Owen Adams - CEO & Director Mark Schney...

27 days ago - Seeking Alpha

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Con...

5 weeks ago - Business Wire

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. ...

5 weeks ago - Business Wire

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director E...

2 months ago - Seeking Alpha

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. “Acadia continued to build momentum in the seco...

2 months ago - Business Wire

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, Augu...

2 months ago - Business Wire

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott ...

2 months ago - Business Wire

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk catal...

2 months ago - Seeking Alpha

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. fi...

2 months ago - Business Wire

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. ...

3 months ago - Business Wire

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for ...

4 months ago - Business Wire

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June...

4 months ago - Business Wire

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Mond...

4 months ago - Business Wire

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role All...

4 months ago - Business Wire

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday.

5 months ago - Benzinga

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Acadia Pharmaceuticals secured another court win on Nuplazid that solidifies its IP position and long-term exclusivity. The commercial business' performance remains slightly underwhelming but there ar...

5 months ago - Seeking Alpha

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation...

5 months ago - Business Wire

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updat...

5 months ago - Seeking Alpha